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Objective: To evaluate patterns of cervical cancer incidence in Peru by examining variation in 2 common his-
topathologic types, squamous cell carcinoma (SCC) and adenocarcinoma (ADC), and analyzing trends over
time. Methods: Data on the incidence of invasive cervical cancer between 1984 and 2006 were obtained
from 3 population-based cancer registries in Peru: Lima, Trujillo, and Arequipa. For each registry, data quality
assessment was performed, crude and age-specific incidence was calculated, and time trends were analyzed.
Results: Overall and SCC incidence varied across registries but incidence of ADC did not. Overall and SCC in-
cidence showed significant declines in Trujillo (Pb0.05) and modest declines in Lima (PN0.05) over time.
ADC incidence showed marginally significant increases among women aged 15–29 years in Trujillo
(P=0.10) and modest increases among young women in Lima (PN0.05). Conclusion: Population-based can-
cer registries were an efficient source of data for evaluating the incidence of cervical cancer once data quality
had been established. Geographic and temporal variations in cervical cancer burden were documented in
Peru. The trends suggest that cervical ADC is increasing among young women in urban Peru, particularly in
Trujillo. We recommend supplementing current Papanicolaou test screening with complementary methods
of cervical cancer control, including human papillomavirus (HPV) vaccination and HPV DNA testing.
© 2011 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.1. Introduction
Cervical cancer is the second most common cancer among women
in low-resource countries, where more than 85% of the global burden
occurs [1,2]. With the introduction of cervical cancer screening pro-
grams based on the Papanicolaou (Pap) test, the incidence of and
mortality from cervical cancer have declined worldwide, notably for
the most prevalent histopathologic type, squamous cell carcinoma
(SCC) [3,4]. However, the opposite trend has been seen for the second
most prevalent type, adenocarcinoma (ADC), the incidence of which
has increased among young women in high-resource countries [5].
Peru, a middle-income country in South America, has some of the
highest incidence and mortality rates of cervical cancer in the world
[2,6], but no well-organized cervical cancer screening program. Pap
test screening has been sparsely implemented in Peru, especially in
rural areas, and suffers from low quality control, insufficient coverage
of women at risk, and poor follow-up of women with abnormal re-
sults [3]. Additional methods of cervical cancer control are needed;
however, the current cervical cancer burden in Peru must be appro-
priately assessed before recommendations can be made.er & Research Institute, 12902
SA. Tel.: +1 813 745 6198;
(C.M. Pierce Campbell).
eration of Gynecology and Obstetrics.We considered that the incidence of cervical SCC and ADC would
vary significantly across Peru, demonstrating the heterogeneity of the
population. We also considered that the incidence of cervical SCC
would show decreasing trends over time, whereas that of cervical
ADC would show increasing trends over time, as has been observed in
high-resource countries. Evaluating the histopathologic profile of cervi-
cal cancer in Peru could influence recommendations for newermethods
of cervical cancer control. If the high incidence of SCC remains
unchanged in Peru, and/or if the incidence of ADC appears to be increas-
ing, additional methods could be suggested, such as human papilloma-
virus (HPV) vaccination or high-risk HPV DNA testing [7–10].
The aim of the present study was therefore to evaluate patterns of
cervical cancer incidence in Peru by examining regional variations in
the 2 most common histopathologic types, SCC and ADC, and by ana-
lyzing differences in these patterns over time using data from 3
population-based cancer registries: Lima, Trujillo, and Arequipa.
2. Materials and methods
In a retrospective study, data on the incidence of cervical cancer
were retrieved and analyzed from 3 population-based cancer regis-
tries covering the largest urban areas of Peru. The Lima Metropolitan
Cancer Registry (1990–1998), the Trujillo Cancer Registry (1984–
2002), and the Arequipa Population-based Cancer Registry (2004–
2006) provided data from the most recent time periods available.Published by Elsevier Ireland Ltd. All rights reserved.
48 C.M. Pierce Campbell et al. / International Journal of Gynecology and Obstetrics 116 (2012) 47–51Peruvian registry directors and the Institutional Review Board at the
University of Michigan approved the study proposal.
To verify data quality, assessment of quality was conducted on
each registry using only cervical cancer data. Quality indicators
were used that were similar to those proposed by the International
Agency for Research on Cancer (IARC) in Cancer Incidence in Five
Continents Volume IX [6], which included the percentage of cases
that were microscopically verified, that were registered from a
death certificate only, that had an unknown basis of diagnosis, and
for which patient age was unknown [6].
Cases diagnosed as invasive cervical cancer in women aged
15 years and older were included. Tumor morphologies were coded
according to the International Classification of Diseases for Oncology,
and grouped into one of the following histopathologic types: (1) SCC,
8050–8078, 8083–8084; (2) ADC, 8140–8141, 8190–8211, 8230–
8231, 8260–8263, 8310, 8380, 8382–8384, 8440–8490, 8560–8569,
8570–8574, 8576; or (3) other carcinoma (all other specified and
unspecified carcinomas). Classification was based on IARC criteria
[6], except that adenosquamous carcinoma (8560–8569) was includ-
ed as ADC. Non-carcinomas and unspecified malignant tumors were
excluded from histopathology-specific analyses, but included in over-
all analyses.
Population data from the 1981, 1993, and 2007 Peruvian censuses
were used to estimate the annual female population size for each regis-
try area (InstitutoNacional de Estadística e Informática de Perú). For the
inter-census years, linear population growth between censuses was as-
sumed. Comparison of the age distribution of the female population
across registry areas showed that the underlying age structure for
women aged 15 years and older was similar across registry areas for
each census year; therefore, the incidence was not age-standardized.
Statistical analyses were completed by SAS/STAT software version
9 (SAS Institute, Cary, NC, USA). The incidence was calculated for each
registry over the appropriate registration time period. The incidence
of cervical cancer overall (all cervical cancer cases) and the
histopathology-specific incidence of SCC and ADC were calculated
and expressed as the number of new cases per 100 000 women per
year. The age-specific incidence was also calculated using 15-year
age groups: 15–29 years, 30–44 years, 45–59 years, 60–74 years,
and ≥75 years. Exact Poisson 95% confidence intervals (CI) were con-
structed via a macro in SAS/STAT software [11]. The incidence of cer-
vical cancer was then assessed for significant changes over time via
linear regression (GLM procedure). The direction of each trend was
determined by the β coefficient, and statistical significance was
based on an α-level of 0.05. Trend analyses were conducted only for
the Lima and Trujillo registries because the Arequipa registry provid-
ed too few years of data.
In addition, the proportion of each histopathologic type was calcu-
lated by using all cervical carcinomas as the denominator. For each
registry, proportions were calculated over the appropriate time peri-
od. Significant differences in the proportion of carcinoma type were
evaluated between pairs of registries via a χ2 test (α=0.05). The pro-
portion of carcinoma types by year was also calculated for Lima and
Trujillo to investigate trends.
3. Results
With regard to the quality assessment of the cervical cancer data
(Table 1), quality indicators for both Lima and Trujillo were within ac-
ceptable limits; however, the proportion of cases that were micro-
scopically verified in Arequipa (99.3%) was above the acceptable
limit (98.0%). Although the data from Arequipa did not meet all of
the international requirements for quality, this registry was included
in the analyses owing to the paucity of cervical cancer data available
in Peru.
The crude and age-specific incidence of cervical cancer overall is
presented with case counts for each registry in Table 2. The overallincidence of cervical cancer of all types differed significantly across
registries: Arequipa (47.2 new cases per 100 000 women per year;
95% CI, 43.4–51.2), Trujillo (36.1; 95% CI, 34.5–37.8), Lima (18.9;
95% CI, 18.4–19.3). The age-specific incidence did not differ between
Arequipa and Trujillo; however, the incidence was significantly
lower in Lima than in Arequipa and Trujillo for the following age
groups: 30–44 years, 45–59 years, 60–74 years, and ≥75 years.
The histopathology- and age-specific incidence is also provided,
together with case counts, in Table 2. The incidence of SCC was signif-
icantly lower in Lima (14.0 new cases per 100 000 women per year;
95% CI, 13.6–14.4) than in Arequipa (29.7; 95% CI, 26.7–33.0) or Tru-
jillo (30.0; 95% CI, 28.6–31.6). The age-specific incidence of SCC
showed similar results to the incidence of cervical cancer overall. In
contrast, the incidence of ADC did not differ significantly across regis-
tries. Only one age group, 45–59 years, had a significantly lower inci-
dence of ADC in Lima than in Trujillo.
Fig. 1 presents time trends in the incidence of cervical cancer across
all ages in Lima and Trujillo. Decreasing trends were found in Lima for
cervical cancer overall (β=−0.103, P=0.250) and SCC (β=−0.029,
P=0.697); however, these trends were not significant. In Trujillo, sig-
nificant decreasing trends were found for cervical cancer overall (β=
−0.479, P=0.011) and SCC (β=−0.345, P=0.024). In contrast, in-
creasing trends were found for ADC-specific incidence in both Lima
(β=0.051, P=0.349) and Trujillo (β=0.050, P=0.239), but neither
trend reached significance.
In Fig. 2, the incidence of cervical cancer over time is shown for
Lima and Trujillo according to age group and histopathology. For cer-
vical cancer overall, significant decreasing trends were found in 1 age
group in Lima (45–59 years, β=−3.280, P=0.005) and several age
groups in Trujillo (30–44 years, β=−1.684, P=0.005; 45–59 years,
β=−2.963, P=0.012; 60–74 years, β=−5.038, P=0.001), with
marginally significant declines in the oldest age group in Trujillo
(≥75 years, β=−7.839, P=0.067). Similarly, for SCC, significant de-
creasing trends were found among age groups in Lima (45–59 years,
β=−2.384, P=0.001) and Trujillo (30–44 years, β=−1.399,
P=0.029; 45–59 years, β=−2.447, P=0.009; 60–74 years, β=
−4.067, P=0.004), again with marginally significant declines in the
oldest age group in Trujillo (≥75 years, β=−4.931, P=0.082). For
ADC, marginally significant increasing trends were found among the
youngest age group in Trujillo (15–29 years, β=0.016, P=0.101);
increasing trends in ADC were also found among younger age groups
in Trujillo (30–44 years, β=0.061, P=0.665; 45–59 years, β=0.232,
P=0.362), and among young women in Lima (15–29 years,
β=0.008, P=0.551; 30–44 years, β=0.096, P=0.467); however,
these trends did not reach significance.
Table 3 presents the proportions of cervical carcinoma type for
each registry. The proportion of SCC was significantly different across
registries (Pb0.0001); the proportion was highest in Trujillo (89.5%),
followed by Lima (82.7%) and Arequipa (72.4%). The proportion of
ADC was significantly higher in Lima (12.7%) than in Arequipa
(7.9%) or Trujillo (7.8%). Linear regression analyses indicated no sig-
nificant time trends in the proportion of carcinomas diagnosed as
SCC for any registry; however, the proportion of carcinomas diag-
nosed as ADC increased significantly in Trujillo (β=0.005, P=0.034).
4. Discussion
The present study examined geographic and temporal differences
in the incidence of histopathology-specific cervical cancer by using
data from 3 population-based cancer registries in Peru. Significant
heterogeneity was found in the incidence of overall cervical cancer
and SCC within Peru, whereas that of ADC was homogeneous. Before
the study, we predicted that overall cervical cancer burden would be
lowest in Lima, the most economically developed area, and greatest
in Trujillo, the least developed area studied; however, the incidence
was highest in Arequipa. Given that the Arequipa registrywas recently
Table 1
Quality assessment of cervical cancer data in Peru according to registry.
Registration
time period
Population
coverage in
2007
Number of cervical
cancer cases
Percentage of
microscopically
verified cases
Percentage of
cases with death
certificate only
Unknown basis
of diagnosis, %
Unknown
age, %
Acceptable data range 75–98 ≤10 ≤10 ≤20
Registry
Lima 1990–1998 4 338 566 6142 90.1 3.1 N/A 0.2
Trujillo 1984–2002 355 202 1837 93.6 3.5 0.2 0.0
Arequipa 2004–2006 413 208 567 99.3a 0.5 0.0 0.0
a Although the percentage of microscopically verified cases was higher than the acceptable range, data from Arequipa were included in the analyses because of the paucity of
cervical cancer data available in Peru.
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in addition to incident cases, which would overestimate the cervical
cancer incidence [12]. Moreover, the observed heterogeneity in inci-
dence may be a result of the disparate time periods analyzed, which
should be taken into consideration when interpreting the findings.
There were declines in overall and SCC-specific cervical cancer in-
cidence over time in both Lima and Trujillo; however, significant de-
clines were found only in Trujillo. Although there is no well-
organized cervical screening program in either region, the declining
rates of SCC might be partly explained by opportunistic screening be-
cause cases could be diagnosed earlier as dysplasia rather than inva-
sive cancer [4]. The lack of significant trends in Lima may have been
due to the limited number of years of data available for analysis:
9 years of data were available for Lima as compared with 19 years
for Trujillo.
Geographic and temporal variations in cervical cancer incidence
may reflect population differences or changes in the distribution of
cervical cancer risk factors or HPV cofactors. The present results
may have been influenced by regional differences or temporal
changes in the prevalence of high-risk HPV types, patterns of high-
risk sexual behaviors (number of sexual partners and early age at
first intercourse), patterns of high-risk reproductive behaviors (highTable 2
Incidence of cervical cancer according to histopathologic type and registry.
Lima (1990–1998)a Trujillo (
Number of cases Incidence (95% CI)b Number
All cases
Crude incidence 6142 18.9 (18.4–19.3) 1837
Age-specific incidence
15–29 years 212 2.1 (1.8–2.4) 46
30–44 years 1761 26.0 (24.8–27.2) 500
45–59 years 2205 61.8 (59.3–64.5) 658
60–74 years 1427 77.6 (73.6–81.8) 447
≥75 years 521 76.1 (69.7–82.9) 186
SCC
Crude incidence 4554 14.0 (13.6–14.4) 1529
Age-specific incidence
15–29 years 134 1.3 (1.1–1.6) 43
30–44 years 1346 19.9 (18.8–21.0) 430
45–59 years 1674 46.9 (44.7–49.2) 532
60–74 years 1041 56.6 (53.2–60.2) 383
≥75 years 350 51.1 (45.9–56.8) 141
ADC
Crude incidence 700 2.2 (2.0–2.3) 134
Age-specific incidence
15–29 years 25 0.2 (0.2–0.4) 1
30–44 years 226 3.3 (2.9–3.8) 44
45–59 years 268 7.5 (6.6–8.5) 61
60–74 years 137 7.5 (6.3–8.8) 18
≥75 years 44 6.4 (4.7–8.6) 10
Abbreviations: ADC, adenocarcinoma; CI, confidence interval; SCC, squamous cell carcinom
a Registration time period.
b The incidence is reported per 100 000 women per year.parity and long-term oral contraceptive use), prevalence of co-
infection with HIV, prevalence of smoking, frequency of Pap screen-
ing, and prevalence of certain sociodemographic characteristics such
as poverty and low levels of education [7,13–15]. Given that the
study examined 3 comparable urban centers, however, we would ex-
pect the above factors to have had a minimal impact on the popula-
tion differences observed.
There was evidence suggesting a rise in the burden of ADC, partic-
ularly among young women in Trujillo. After examining changes in
the proportion of cervical carcinoma type, we found that the propor-
tion of ADC increased significantly over time in Trujillo. There were
also slight trends toward increasing incidence of ADC in Lima and
Trujillo; however, these trends were not significant. When time
trends were examined for each age group, we found increasing
rates of ADC primarily among young women in both Lima and Truji-
llo; however, these trends were only marginally significant in Trujillo.
Nonetheless, these findings indicate an important development in the
evolving cervical cancer burden of Peru.
Similar increases in the burden of ADC have been found among
young women in high-resource countries such as the United States
and Canada [16,17], in western Europe [18], and more recently in
lower-income regions such as Goiânia, Brazil [19]. The rise in ADC1984–2002)a Arequipa (2004–2006)a
of cases Incidence (95% CI)b Number of cases Incidence (95% CI)b
36.1 (34.5–37.8) 567 47.2 (43.4–51.2)
2.9 (2.1–3.8) 10 2.9 (1.4–5.2)
50.4 (46.1–55.1) 146 54.4 (45.9–64.0)
119.5 (110.6–129.0) 212 128.3 (111.6–146.8)
163.4 (148.6–179.3) 140 167.1 (140.5–197.1)
166.9 (143.8–192.7) 59 148.6 (113.2–191.7)
30.0 (28.6–31.6) 357 29.7 (26.7–33.0)
2.7 (1.9–3.6) 6 1.7 (0.6–3.7)
43.4 (39.4–47.7) 89 33.2 (26.6–40.8)
96.7 (88.6–105.2) 131 79.3 (66.3–94.1)
140.0 (126.4–154.8) 92 109.8 (88.5–134.6)
126.5 (106.5–149.2) 39 98.3 (69.9–134.3)
2.6 (2.2–3.1) 39 3.3 (2.3–4.4)
0.1 (0.0–0.4) 1 0.3 (0.0–1.6)
4.4 (2.2–6.0) 13 4.8 (2.6–8.3)
11.1 (8.5–14.2) 15 9.1 (5.1–15.0)
6.6 (3.0–10.4) 8 9.6 (4.1–18.8)
9.0 (4.0–16.5) 2 5.0 (0.6–18.2)
a.
Fig. 1. Trends in the incidence of histopathology-specific cervical cancer according to
registry. The incidence is reported per 100 000 women per year. There was a significant
decrease in overall and SCC incidence over time in Trujillo (*Pb0.05). Abbreviations:
ADC, adenocarcinoma; SCC, squamous cell carcinoma.
Table 3
Proportion of cervical carcinomas according to histopathologic type and registry.
Lima
(1990–1998)a
Trujillo
(1984–2002)a
Arequipa
(2004–2006)a
P value
SCC 0.827 0.895 0.724 b0.0001 (L vs A)
b0.0001 (L vs T)
b0.0001 (A vs T)
ADC 0.127 0.078 0.079 b0.05 (L vs A)
b0.0001 (L vs T)
Other 0.046 0.027 0.197f b0.0001 (L vs A)
b0.05 (L vs T)
b0.0001 (A vs T)
Abbreviations: ADC, adenocarcinoma; SCC, squamous cell carcinoma; A, Arequipa; L,
Lima; T, Trujillo.
a Registration time period.
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may not adequately detect ADC precursor lesions because these le-
sions are located higher in the endocervical canal, making them less
accessible than SCC lesions for testing [7,20,21]. In addition, Pap test
has low sensitivity for the detection of ADC (45%–76%), and produces
more false negatives as compared with SCC lesions [20]. The inability
to adequately detect ADC precursor lesions ultimately allows invasive
ADC to develop without detection, and is a limitation of conventional
screening.
One of the strengths of the present study is its novelty. Few stud-
ies have been published using cancer registry data from low-resourceFig. 2. Trends in cervical cancer incidence according to age group, histopathology, and regist
time as indicated: significant decrease, *Pb0.05; marginally significant decrease, **Pb0.10;countries, such as Peru, to describe intra-country variation in cervical
cancer incidence and histopathology. Utilizing existing data from
population-based cancer registries facilitated a time- and cost-
efficient method of describing cancer burden in a population, which
is especially beneficial in low- and middle-income countries. Howev-
er, data quality should be established first.
The results of the data quality assessment showed that cervical
cancer data quality was high in Lima and Trujillo; however, Arequipa
had a high proportion of cases that were microscopically verified
(99.3%). Although a value close to 100% is desirable in high-income
countries, it is problematic in low-resource countries, where it typi-
cally suggests an over-reliance on pathology laboratories in diagnos-
ing cervical cancer cases, and/or an inability to locate cases
diagnosed by other methods [22]. In low-resource countries, the like-
lihood is greater that cervical cancer cases do not enter the healthcare
system; therefore, the identification of cases by other means, such as
death certificates, is particularly important. Arequipa was included in
the analyses even though the data did not meet international quality
requirements; however, data quality should be considered when
interpreting the data.
As is the case with all cancer registry data, changes in the number
of cases, missing data, and misclassification of histopathology diagno-
ses are capable of altering the incidence. In terms of population de-
nominators, we assumed that there were no errors in population
counts provided by each census and assumed linear populationry. The incidence is reported per 100 000 women per year. The incidence changed over
marginally significant increase, ***Pb0.10.
51C.M. Pierce Campbell et al. / International Journal of Gynecology and Obstetrics 116 (2012) 47–51growth between censuses. In terms of time trend analyses, we had in-
sufficient data to assess trends in Arequipa, and there was little over-
lap in registration time periods across registries, which prevented us
frommaking direct comparisons. In addition, even though the Trujillo
cancer registry met international data quality requirements, fluctua-
tions were observed in age-specific cervical cancer incidence over
time, which may reflect local attempts to introduce cervical screening
programs targeting specific age groups. Nevertheless, we believe that
the study provides an adequate evaluation of cervical cancer histopa-
thology across the 3 Peruvian cancer registries.
The study showed that histopathology-specific cervical cancer in-
cidence varied both across regions of Peru and over time in certain
registries and age groups. There were also trends suggesting an in-
crease in ADC burden among young women, particularly in Trujillo.
Population-based cancer registry data proved to be an efficient source
for evaluating cervical cancer patterns among Peruvian women once
data quality had been established. The results from the study should
be used to influence decisions regarding complementary screening
methods in Peru. Because ADC may be increasing among young
women in urban areas of Peru, we recommend supplementing cur-
rent Pap test screening with HPV vaccination and HPV DNA testing,
which may be more capable of reducing the cervical cancer burden
than cytology-based methods alone [7–10].Acknowledgments
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